In this Urology Times educational supplement, we review the importance of understanding the CRPC–mCRPC transition in order to optimize standard screening procedures and identify patients with early metastatic disease who may benefit from therapeutic intervention.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.